The effect of Cariprazine on hostility associated with schizophrenia: Post hoc analyses from 3 randomized controlled trials

Journal of Clinical Psychiatry

Volumn 77, Issue 1, 2016, Pages 109-115

  Citrome, Leslie ^a   Durgam, Suresh ^b   Lu, Kaifeng ^b   Ferguson, Paul ^c   Laszlovszky, István ^d  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Prescott Medical Communications Group   (United States)

^d GEDEON RICHTER LTD   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CARIPRAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ADULT; AGGRESSION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DSM-IV; GOOD CLINICAL PRACTICE; HOSTILITY; HUMAN; INTENTION TO TREAT ANALYSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; ADOLESCENT; FEMALE; MALE; META ANALYSIS (TOPIC); MIDDLE AGED; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HOSTILITY; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957800910     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10192     Document Type: Article

References (44)

1. Volavka J, Czobor P, Derks EM, et al; EUFEST Study Group. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2011;72(7):955-961. doi:10.408/JCP.10m06529 PubMed
2. Walsh E, Buchanan A, Fahy T. Violence and schizophrenia: examining the evidence. Br J Psychiatry. 2002;180(6):490-495. doi:10.192/bjp. 180.6.490 PubMed
3. Citrome L, Volavka J. The psychopharmacology of violence: making sensible decisions. CNS Spectr. 2014;19(5):411-418. doi:10.1017/S1092852914054 PubMed
4. Volavka J, Citrome L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull. 2011;37(5):921-929. doi:10.1093/schbul/sbr041 PubMed
5. Volavka J, Czobor P, Citrome L, et al. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr. 2014;19(5):374-381. doi:10.1017/S10928529130849 PubMed
6. Witt K, van Dorn R, Fazel S. Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS ONE. 2013;8(2):e55942. doi:10.1371/journal.pone.05942 PubMed
7. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261 PubMed
8. Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv. 2001;52(11):1510-1514. doi:10.176/api.ps.52.1.1510 PubMed
9. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol. 1995;15(4):243-249. doi:10.1097/04714-195080-02 PubMed
10. Volavka J, Czobor P, Citrome L, et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry. 2005;66(11):1362-1366. doi:10.408/JCP.v6n103 PubMed
11. Ahmed AO, Hunter KM, Van Houten EG, et al. Cognition and other targets for the treatment of aggression in people with schizophrenia. Ann Psychiatry Ment Health. 2014;2(1):1004.
12. Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006;63(6):622-629. doi:10.101/archpsyc.63.6.62 PubMed
13. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2-3):450-457. doi:10.1016/j.schres.2013.1.041 PubMed
14. Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367-373.
15. Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixeddose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574-e1582.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
17. Guy W. Clinical Global Impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976:217-222.
18. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale Manual. North Tonawanda, NY: Multi-Health Systems; 2000.
19. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53(3):983-997. doi:10.2307/25358 PubMed
20. Topiwala A, Fazel S. The pharmacological management of violence in schizophrenia: a structured review. Expert Rev Neurother. 2011;11(1):53-63. doi:10.1586/ern. 10.180 PubMed
21. Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for longterm treatment. Int J Clin Pract. 2008;62(8):1237-1245. doi:10.1/j.1742-1241.208.01797.x PubMed
22. Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol. 2004;24(2):225-228. doi:10.1097/01.jcp. 017424.05703.29 PubMed
23. Citrome L. Clozapine for schizophrenia: lifethreatening or life-saving treatment? clozapine, despite its side effect burden, may be the most effective and have the lowest mortality risk among all available antipsychotics. Curr Psychiatr. 2009;8(12):56-63.
24. Chengappa KN, Goldstein JM, Greenwood M, et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther. 2003;25(2):530-541. doi:10.1016/S0149-2918 (03) 8094-2 PubMed
25. Citrome L, Casey DE, Daniel DG, et al. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv. 2004;55(3):290.294. doi:10.176/api.ps.5.3.290 PubMed
26. Citrome L, Volavka J, Czobor P, et al. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry. 2006;67(4):638.642. doi:10.408/JCP.v67n0415 PubMed
27. Swanson JW, Swartz MS, Van Dorn RA, et al. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry. 2006;63(5):490.499. doi:10.101/archpsyc.63.5.490 PubMed
28. Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D (3) receptor-preferring, D (3)/D (2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328.340. doi:10.124/jpet.109.160432 PubMed
29. Kiss B, Horti F, Bobok A. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res. 2012;136(suppl 1):S190. doi:10.1016/S0920-964 (12) 7058-1
30. Slifstein M, Abi-Dargham A, D'Souza DC, et al. cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical PET study with [11C]-(+)-PHNO. Neuropsychopharmacology. 2013;38(S2):S520.
31. Cho DI, Zheng M, Kim KM. Current perspectives on the selective regulation of dopamine D. and D. receptors. Arch Pharm Res. 2010;33(10):1521.1538. doi:10.107/s1272-010-105-8
32. Gross G, Wicke K, Drescher KU. Dopamine D. receptor antagonism.still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(2):155.166. doi:10.107/s0210-012-0806-3 PubMed
33. Laszy J, Laszlovszky I, Gyertyan I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl). 2005;179(3):567.575. doi:10.107/s0213-04-2096-z PubMed
34. Millan MJ, Buccafusco JJ, Loiseau F, et al. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol. 2010;13(8):1035.1051. doi:10.1017/S14614571075 PubMed
35. Sokoloff P, Diaz J, Le Foll B, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2006;5(1):25.43. doi:10.2174/187152706784151 PubMed
36. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today. 2005;10(13):917.925. doi:10.1016/S1359-646 (05) 03491-4 PubMed
37. Kiss B, Laszlovszky I, Horvath A, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):515.528. doi:10.107/s0210-08-0308-5 PubMed
38. Schwartz JC, Diaz J, Pilon C, et al. Possible implications of the dopamine D (3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev. 2000;31(2-3):277-287. doi:10.1016/S0165-0173 (9) 043-0 PubMed
39. Gyertyán I, Sághy K, Laszy J, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):529-539. doi:10.107/s0210-08-031-x PubMed
40. Duman RS, Duric V, Banasr M, et al. Cariprazine exhibits dopamine D3 receptordependent antidepressant-like activity in the chronic unpredictable stress model of anhedonia. Neuropsychopharmacology. 2012;38(suppl 1):S84.
41. Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamine D (3)-receptorpreferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013;226(1):91-100. doi:10.107/s0213-012-2896-5 PubMed
42. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30(2):114-126. doi:10.107/s12325-013-06-7 PubMed
43. Volavka J, Zito JM, Vitrai J, et al. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol. 1993;13(4):287-289.
44. Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr Res. 1999;35(suppl):S23-S33.